Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;130(8):1662-1673.
doi: 10.1002/jso.27839. Epub 2024 Sep 30.

Omission of Chemoradiation in Locally Advanced Rectal Adenocarcinoma: Evaluation of PROSPECT in a National Database

Joanna T Buchheit  1   2 , Lauren M Janczewski  1   2 , Amy Wells  2 , Ashley N Hardy  2 , John D Abad  2 , David J Bentrem  1   2   3 , Amy L Halverson  1   2 , Akhil Chawla  1   2   3
Affiliations

Omission of Chemoradiation in Locally Advanced Rectal Adenocarcinoma: Evaluation of PROSPECT in a National Database

Joanna T Buchheit et al. J Surg Oncol. 2024 Dec.

Erratum in

Abstract

Background and objectives: The PROSPECT trial showed noninferiority of neoadjuvant chemotherapy (NAC) with selective chemoradiation (CRT) versus CRT alone. However, trial results are often difficult to reproduce with real-world data. Pathologic outcomes and overall survival (OS) were evaluated by neoadjuvant strategy in locally advanced rectal adenocarcinoma patients in a national database.

Methods: The 2012-2020 National Cancer Database was queried for clinical T2N1 and T3N0-1 rectal adenocarcinoma patients with definitive resection. Patients were categorized by neoadjuvant treatment with CRT alone, NAC alone, and NAC with CRT. Outcomes included R0 resection, pathologic complete response (PCR), and OS.

Results: Of 18 892 patients, 16 126 (85.4%) received CRT, 1018 (5.4%) NAC, and 1748 (9.3%) NAC with CRT. Patients with NAC alone or NAC with CRT were more likely to have stage-III disease, private insurance, and academic facility treatment (all p < 0.001). NAC alone had lower adjusted odds of an R0 resection (OR 0.72; 95%CI 0.54-0.95) and PCR (OR 0.77; 95%CI 0.64-0.93). NAC with CRT demonstrated improved OS (HR 0.71; 95%CI 0.61-0.82), with no difference between NAC and CRT alone. Among patients who received adjuvant chemotherapy, no differences in OS were seen.

Conclusions: Patients who received NAC alone had worse pathologic outcomes. NAC had similar OS to CRT and NAC with CRT showed improved OS.

Keywords: chemoradiation; locally advanced rectal adenocarcinoma; neoadjuvant therapy; overall survival; pathologic complete response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve comparing overall survival by neoadjuvant treatment strategy among patients with clinical T2N1, T3N0, and T3N1 rectal adenocarcinoma.
Figure 2
Figure 2
Kaplan–Meier curve comparing overall survival by neoadjuvant treatment strategy among patients who received adjuvant chemotherapy for clinical T2N1, T3N0, and T3N1 rectal adenocarcinoma.
See this image and copyright information in PMC

References

    1. Peeters K. C. M. J., Marijnen C. A. M., Nagtegaal I. D., et al., “The TME Trial After a Median Follow‐Up of 6 Years: Increased Local Control but no Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma,” Annals of Surgery 246, no. 5 (November 2007): 693–701, 10.1097/01.sla.0000257358.56863.ce. - DOI - PubMed
    1. Swedish Rectal Cancer T., Cedermark B., Dahlberg M., et al., “Improved Survival With Preoperative Radiotherapy in Resectable Rectal Cancer,” New England Journal of Medicine 336, no. 14 (April 1997): 980–987, 10.1056/NEJM199704033361402. - DOI - PubMed
    1. Kapiteijn E., Marijnen C. A. M., Nagtegaal I. D., et al., “Preoperative Radiotherapy Combined With Total Mesorectal Excision for Resectable Rectal Cancer,” New England Journal of Medicine 345, no. 9 (August 2001): 638–646, 10.1056/NEJMoa010580. - DOI - PubMed
    1. Sauer R., Becker H., Hohenberger W., et al., “Preoperative Versus Postoperative Chemoradiotherapy for Rectal Cancer,” New England Journal of Medicine 351, no. 17 (October 2004): 1731–1740, 10.1056/NEJMoa040694. - DOI - PubMed
    1. André T., Boni C., Mounedji‐Boudiaf L., et al., “Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer,” New England Journal of Medicine 350, no. 23 (June 2004): 2343–2351, 10.1056/NEJMoa032709. - DOI - PubMed